
    
      To demonstrate that reconverting type 2 diabetic patients from insulin treatment to oral
      treatment using pioglitazone in combination with or without glimepiride is possible without
      deterioration of blood glucose control.

      Primary aim is to maintain glycaemic control (HbA1c) defined as an increase in HbA1c of not
      more than 0.5 % after 6 months of treatment (visit 7) compared to baseline HbA1c value
      (screening visit V1).
    
  